PubRank

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial ID NCT01193257

PubWeight™ 46.59‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01193257

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015 4.44
2 Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011 2.17
3 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
4 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
5 End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011 1.94
6 Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2011 1.64
7 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
8 Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 2013 1.26
9 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
10 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
11 Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl 2013 1.11
12 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
13 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
14 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
15 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
16 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
17 Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011 0.94
18 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
19 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
20 Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol 2012 0.91
21 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
22 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
23 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
24 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
25 Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014 0.86
26 Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013 0.85
27 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
28 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
29 Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014 0.82
30 Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2010 0.82
31 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
32 Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. Ther Adv Urol 2012 0.80
33 Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014 0.80
34 Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther 2012 0.79
35 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
36 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
37 Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis. Clin Pharmacol Ther 2015 0.78
38 Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer. Front Endocrinol (Lausanne) 2012 0.76
39 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
40 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
41 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
42 The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. P T 2012 0.75
43 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
Next 100